Lobectomy versus stereotactic ablative radiotherapy for medically operable patients with stage IA non-small cell lung cancer: A virtual randomized phase III trial stratified by age.

Young-Seok SeoHak Jae KimHong Gyun WuSun Mi ChoiSamina Park

Published in: Thoracic cancer (2019)

The Markov model showed no statistically significant difference in the expected overall survival in stage IA NSCLC patients who were older than 75 years and had undergone SABR or lobectomy.

Keyphrases

phase iii
open label
clinical trial
double blind
placebo controlled
phase ii
small cell lung cancer
brain metastases
early stage
physical activity
radiation therapy
advanced non small cell lung cancer
middle aged
locally advanced
community dwelling
free survival